Transplantation of skeletal muscle came into play in the early 1990s and aimed to restore dystrophin production in patients with Duchennemusculardystrophy(DMD). Skeletal muscle seemed to be a suitable target forcelltherapy, since muscle fibers mainly consist of postmitoticcellsand there is limitedcellturnover.
Stemcellsnot only regenerate tissue but also reduce harmful inflammation and limit the formation of fibrotic scar tissue. By doing so, they help create a more supportive environment for healing and muscle function. ConclusionStemcelltherapy represents a significant breakthrough in the management ofmusculardystrophy.
Musculardystrophies comprise >50 monogenic disorders in which gene defects cause progressive degeneration and atrophy of striated muscle. The most frequent and among the most severe is Duchennemusculardystrophy(DMD), an X-linkeddiseasecaused by loss-of-function mutations in DMD, encoding dystrophin. Patients develop early muscle weakness and typically lose ambulation in late childhood ...
Musculardystrophyis a group of inherited genetic disorders characterized by progressive muscle weakness and degeneration. The most common forms ofmusculardystrophyinclude Duchenne, Becker, and myotonicdystrophy, among others. Current treatment options focus on managing symptoms and slowing the progression of thediseasebut do not offer a cure.Stemcelltherapy has emerged as a ...
Stemcellsare a valuable tool inmusculardystrophyresearch in two ways: by acting as models for thedisease, and in their role as a direct treatment for the condition.
Stemcelltherapy holds promise as a treatment formusculardystrophyby providingcellsthatcanboth deliver functional muscle proteins and replenish thestemcellpool. This article reviews the current state of research on myogenicstemcellsand ...
Increasing evidence supports the contributing role of satellitecellsin Duchennemusculardystrophy(DMD), a lethal degenerative musclediseasecaused by loss of dystrophin.
